Guilford, Connecticut, August 20, 2026
Hyperfine announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s latest Optive AI™ software update for the Swoop® portable MRI system, introducing improvements in image quality, scanning workflow and three-dimensional brain imaging capabilities. The clearance represents Hyperfine’s second FDA-cleared software package since the launch of its next-generation Swoop system in mid-2025 and expands the capabilities of its portable, ultra-low-field brain MRI platform. The new software is designed to improve image quality across Swoop imaging sequences, strengthen noise correction in challenging clinical environments and make system operation more intuitive for healthcare professionals. A new isotropic T1 imaging sequence also provides thinner slices and consistent resolution across imaging planes, supporting applications where three-dimensional visualization may be clinically useful. The Swoop system is designed to operate without the electromagnetic shielding required by conventional high-field MRI systems, allowing brain imaging in locations such as intensive care units and emergency departments where conventional MRI access can be difficult. For cGxP.wire readers, the key development is the FDA clearance of a software-driven upgrade that expands the clinical utility of an already-cleared portable imaging platform. Hyperfine plans to begin rolling out the updated software to existing and new Swoop users in the United States in September 2026.
Optive AI Improves Portable MRI Image Quality
The latest Optive AI software update is designed to improve image quality across Swoop system sequences by advancing Hyperfine’s proprietary noise-cancellation capabilities. This is particularly relevant to portable MRI because the Swoop system is designed for use in electromagnetically noisy point-of-care environments, including intensive care and emergency departments. Conventional high-field MRI systems typically rely on shielded environments to control electromagnetic interference, while Swoop’s design allows imaging to be performed in locations where such infrastructure may not be practical. Hyperfine said the new software improves noise correction across sequences to provide clearer and more consistent images, with the goal of moving image quality closer to that associated with higher-field systems. The update also introduces a more guided user interface that allows operators to view sequences and images as they are being acquired. This workflow change is intended to make scanning easier and provide operators with more immediate visibility into image acquisition. For the clinical imaging market, these improvements are important because portable MRI depends not only on device mobility but also on obtaining usable images in environments where traditional imaging infrastructure may be unavailable. The FDA clearance therefore strengthens the software component of Hyperfine’s portable MRI platform, rather than representing the introduction of an entirely new MRI device.
New Isotropic T1 Sequence Expands Imaging Capability
A major feature of the cleared software is the introduction of a new isotropic T1 imaging sequence, which provides thinner slices and consistent resolution across different imaging planes. This capability is intended to strengthen three-dimensional visualization and may be particularly useful in clinical situations where spatial information supports assessment of anatomical structures. Hyperfine highlighted potential relevance to post-operative tumor follow-up, where visualization across multiple planes can support clinical evaluation. The addition represents an important software-driven expansion for an ultra-low-field portable MRI platform because it provides an imaging capability that was not previously available on the Swoop system in this form. The company said the software architecture also establishes a foundation for potential future applications, including neurosurgery contrast imaging and quantitative MRI, although these are future possibilities rather than capabilities established by the current FDA clearance. For cGxP.wire readers following MedTech imaging innovation, the development demonstrates how software and AI-based image processing can expand the clinical functionality of existing imaging hardware. The new sequence also reinforces Hyperfine’s strategy of using frequent software updates to progressively improve the clinical utility of portable MRI while maintaining the system’s ultra-low-field architecture.
Advertisement
Hyperfine Expands Swoop Across Care Settings
The FDA clearance further advances Hyperfine’s strategy of making portable brain MRI available at multiple points of professional care. The Swoop system is FDA cleared for brain imaging in patients of all ages and is intended for situations where a full conventional diagnostic MRI examination is not clinically practical. Its portability allows the system to be brought directly to patients rather than requiring them to be transported to a conventional MRI suite. The latest software update adds capabilities intended to improve both image acquisition and interpretation support while maintaining the system’s point-of-care design. Hyperfine plans to begin the U.S. rollout in September 2026, making the software available to both existing and new Swoop system users. From a cGxP.wire perspective, the most significant aspect of the announcement is the combination of FDA-cleared AI software, portable ultra-low-field MRI, improved image quality and expanded imaging sequences. The update does not represent a new disease indication or a new regulatory approval for a separate imaging device; instead, it enhances an existing cleared platform. As Hyperfine continues developing its software architecture, future regulatory clearances and clinical validation will determine how broadly additional capabilities can be incorporated into portable brain imaging. The current clearance nevertheless represents another step toward expanding accessible MRI imaging beyond traditional hospital radiology environments.
Source:Hyperfine press relese
